The G5 Santé is pleased with the progress of the new LEEM / CEPS framework agreement towards recognising industrial investments and supporting exports, but would have liked to see more measures supporting production in France.

Paris, 5 March 2021 – After long months of discussions, a new framework agreement was signed today between the presidents of the CEPS (French Economic Committee for Health Products) and the LEEM (French Union of Pharmaceutical Companies).

The G5 Santé salutes the strengths of this new framework agreement and is delighted to have been heard by public authorities, in particular on the recognition of industrial investments, the creation of a measure to support export prices and the introduction of the criterion of the place of production for the fixing of prices. It also recognises the provisions of this new framework agreement in favour of innovation, deadlines, the taking into account of developments in R&D and the need to adapt the economic models for medicinal products.

All of these improvements will need to be transposed into practice so that their application reflects the founding will of this new framework agreement, which must not be open for misinterpretation.

This is why the G5 Santé will remain very attentive to the effective implementation of this new framework agreement and of the Ministerial Orientation Letter (LOM) addressed to the President of the CEPS and made public on 1 March, in particular on the consideration of investments, production policies and export capacities in all future conventional negotiations.

The G5 Santé will be particularly vigilant on the implementation of this new agreement concerning ASMR (Improvement in Actual Medical Benefit) 5 products manufactured in Europe, and particularly in France, in medical situations where the supply is not sufficient. The G5 Santé deplores that the possibility of a specific measure in support of a facial price for these products was not included in this new framework agreement, though it would have been neutral for health insurance costs. The industrial and employment consequences of this shortcoming in France will play out over the short, medium and long term.

The G5 Santé intends to continue the constructive dialogue it has established with public authorities. We can no longer go back to making the same mistakes of the past, and this is a condition sine qua non for returning our country to the leading pack of industrial nations in the health industry. The strength of our industry is that it forms the crucible for the development of life-saving innovations for patients.



Now and in particular in preparation for the upcoming meeting of the French Strategic Council for the Healthcare Industries (CSIS), the G5 Santé will continue to put forth constructive proposals in favour of the development of R&D and innovations, a reform of evaluation by the HAS (French High Health Authority) and an increase in production capacities in France, among other topics.




About the G5 Santé (

The G5 Santé, which speaks on behalf of the French health industry, is a think-tank that includes the global CEOs of the main French healthcare and life science companies (Guerbet, Ipsen, LFB, Pierre Fabre, Sanofi, Servier, Théa and bioMérieux).


These companies chose France as a platform for their international development and have made R&D and manufacturing activities their priority. The members of the G5 Santé share 5 ambitions: win recognition of the contribution made by the life science industry as a key player in the public health and health independence of France, contribute to the recovery of France’s competitiveness, make a strong commitment to French biomedical research excellence, develop patient access to health solutions and support biotechnologies and new technologies.



Press Contact

Didier Véron, President of the G5 Santé

Tel.: 01 69 82 72 97 or 06 08 56 76 54